Wolters Kluwer Celebrates the 25th Anniversary of UpToDate with Launch of 25th Specialty, Anesthesiology
Wolters Kluwer Health announced today that UpToDate ®, the acclaimed evidence-based clinical decision support (CDS) resource, is commemorating its 25 th anniversary with the launch of its 25 th clinical specialty, anesthesiology.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171005005691/en/
In 1992, Dr. Burton “Bud” Rose, a renowned nephrologist and medical textbook author, created UpToDate in the basement of his house. Initially a nephrology-focused disease reference tool accessed via floppy disk, UpToDate has since grown to become one of the most trusted and indispensable clinical resources used by clinicians around the world to diagnose and treat patients.
Denise Basow, MD, President and CEO of Clinical Effectiveness at Wolters Kluwer, said, “Dr. Bud Rose’s real genius was to say, ‘Instead of writing about a particular disease, let’s write about the specific clinical questions that a clinician has, apply the best evidence to answer those questions, and then make very specific recommendations for care.’” She adds, “Today with UpToDate, we are changing more than 300,000 medical decisions every day in more than 180 countries.”
Over the past 25 years, UpToDate has grown as a vital clinical resource to include more than 10,500 clinical topics in 25 specialties. A clinical faculty of more than 6,500 physician authors, editors, and peer-reviewers from 53 countries apply their deep clinical domain expertise to critically evaluate available medical literature and produce original content in a succinct, searchable format that can be quickly and easily accessed at the point of care. Today, more than 1.3 million clinicians in 187 countries consult UpToDate via the website and mobile app, viewing more than 32 million topics per month.
Watch our special UpToDate 25th-anniversary video: https://youtu.be/23GYp2uWaUg
The Latest Evidence to Support the Anesthesiology Specialty
In concert with its 25th anniversary, UpToDate introduces its 25th specialty, anesthesiology. This new specialty covers anesthesia topics related to surgical procedures and other interventions, pain management, opioid avoidance, blood transfusion, and postoperative critical care. Led by Editors-in-Chief, Roberta Hines, MD; Stephanie B. Jones, MD; and Lena S. Sun, MD, the topics in the specialty are written to assist anesthesiologists and nurse anesthetists with finding the best evidence to manage perioperative care for complex patients undergoing common and uncommon procedures, including preoperative consultation, intraoperative anesthetic management, postoperative acute care, and optimal pain management. The new specialty is also a vital resource for general practice clinicians as well as specialists such as surgeons who routinely care for patients together with anesthesiologists.
The specialty’s actionable, evidence-based content is authored, edited and reviewed by 190 world-renowned anesthesiology experts. With 271 topics associated with anesthesiology, UpToDate provides comprehensive coverage complemented by 897 graphics and 96 recommendations that are graded to specify the strength of the recommendations and the quality of their underlying evidence. Additionally, 19 patient education topics provide clinical guidance that can be shared with patients. The specialty’s content will continue to expand in the coming years.
“The practice of anesthesia continues to grow more complex and challenging, as patients with significant medical comorbidities increasingly undergo complicated surgical procedures. As we commemorate a quarter-century of helping clinicians make the best care decisions, we’re committed to supporting anesthesiologists and clinicians in other specialties alike with comprehensive, trustworthy guidance from experts in the field,” said Dr. Basow.
About Wolters Kluwer
Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2016 annual revenues of €4.3 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and the organization, visit http://www.wolterskluwer.com/, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.
Wolters Kluwer | Clinical Effectiveness
André Rebelo, +1 781-392-2411
Public & Analyst Relations Manager, UpToDate
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar15.12.2017 22:13 | Pressemelding
Celltrion, Inc. (KOSDAQ: 068270) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that Herzuma® (trastuzumab biosimilar) be granted marketing authorization in the European Union (EU) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP’s opinion will now be sent to the European Commission (EC) for final review. Herzuma® is a biosimilar to Herceptin®i, a breast cancer and gastric cancer treatment antibody biologic drug developed by Genentech and marketed by Roche. Herceptin® is a blockbuster drug which had worldwide sales of CHF 6.8 billionii (US$6.8 billion) in 2016, of which CHF 2.1 billioniii (US$2.1 billion) was in
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 12:34 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712
Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 12:21 | Pressemelding
Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr
Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 11:38 | Pressemelding
A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L
Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million15.12.2017 11:00 | Pressemelding
Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”). Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes. “The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including a
AML BitCoin Enters Phase II of ICO15.12.2017 09:00 | Pressemelding
NAC Foundation, LLC announces today that the initial coin offering for the AML BitCoin – the world’s only patent-pending compliant digital currency – has been extended for another month to accommodate a torrent of last minute, new coin purchasers and the demands of thousands of current owners of the coin, who have had difficulty navigating the process of establishing the specialized wallet required to hold the innovative digital currency. This second phase of the AML BitCoin initial coin offering will see an increase in the price of the coin, from US $1.00 to US $1.25. The company has already been contacted by prospective purchasers in the slightly higher priced Phase II, and anticipates a further price increase to US $1.50 within a week or two. HitBTC, one of the world’s largest and most active digital currency exchanges, was prepared to list the AML BitCoin for trading on
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom